ID TXDP2_PARLU Reviewed; 37 AA. AC P83257; DT 28-NOV-2002, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 1. DT 02-OCT-2007, entry version 33. DE Delta-palutoxin IT2 (Delta-paluIT2). OS Paracoelotes luctuosus (Spider). OC Eukaryota; Metazoa; Arthropoda; Chelicerata; Arachnida; Araneae; OC Araneomorphae; Entelegynae; Amaurobiidae; Paracoelotes. OX NCBI_TaxID=185217; RN [1] RP PROTEIN SEQUENCE, FUNCTION, AND MASS SPECTROMETRY. RC TISSUE=Venom; RX MEDLINE=20428467; PubMed=10971590; RA Corzo G., Escoubas P., Stankiewicz M., Pelhate M., Kristensen C.P., RA Nakajima T.; RT "Isolation, synthesis and pharmacological characterization of delta- RT palutoxins IT, novel insecticidal toxins from the spider Paracoelotes RT luctuosus (Amaurobiidae)."; RL Eur. J. Biochem. 267:5783-5795(2000). RN [2] RP FUNCTION, TOXIC DOSE, SYNTHESIS, MUTAGENESIS OF VAL-3; ASP-5; GLN-7; RP ARG-8; ARG-8; SER-11; TRP-12; TRP-12; SER-13; TYR-16; ASP-19; TYR-21; RP TYR-22; SER-24; ARG-26; MET-28; TYR-30; ARG-32; ARG-34; ASN-35; ASN-36 RP AND SER-37, AND SITE. RX PubMed=15683238; DOI=10.1021/bi048434k; RA Corzo G., Escoubas P., Villegas E., Karbat I., Gordon D., Gurevitz M., RA Nakajima T., Gilles N.; RT "A spider toxin that induces a typical effect of scorpion alpha-toxins RT but competes with beta-toxins on binding to insect sodium channels."; RL Biochemistry 44:1542-1549(2005). RN [3] RP STRUCTURE BY NMR. RX PubMed=15726637; DOI=10.1002/prot.20424; RA Ferrat G., Bosmans F., Tytgat J., Pimentel C., Chagot B., Gilles N., RA Nakajima T., Darbon H., Corzo G.; RT "Solution structure of two insect-specific spider toxins and their RT pharmacological interaction with the insect voltage-gated Na+ RT channel."; RL Proteins 59:368-379(2005). CC -!- FUNCTION: Binds at site 4 of sodium channels and inhibits the fast CC inactivation of cockroach channels. This toxin is active only on CC insects. Has a potent activity against S.litura larvae. CC -!- SUBCELLULAR LOCATION: Secreted. CC -!- TISSUE SPECIFICITY: Expressed by the venom gland. CC -!- DOMAIN: The presence of a 'disulfide through disulfide knot' CC structurally defines this protein as a knottin. CC -!- MASS SPECTROMETRY: Mass=4114.6; Method=MALDI; Range=1-37; CC Source=PubMed:10971590; CC -!- TOXIC DOSE: LD(50) is 24.2 ng/mg body weight of lepidoptera CC larvae. CC -!- SIMILARITY: Belongs to the mu-agatoxin family. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR PDB; 1V91; NMR; A=1-37. DR GO; GO:0005576; C:extracellular region; NAS:UniProtKB. DR GO; GO:0019871; F:sodium channel inhibitor activity; IDA:UniProtKB. DR GO; GO:0009405; P:pathogenesis; IDA:UniProtKB. DR InterPro; IPR009243; Toxin_7. DR Pfam; PF05980; Toxin_7; 1. DR PROSITE; PS60015; MU_AGATOXIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Amidation; Direct protein sequencing; KW Ionic channel inhibitor; Knottin; Neurotoxin; Secreted; KW Sodium channel inhibitor; Toxin. FT PEPTIDE 1 37 Delta-palutoxin IT2. FT /FTId=PRO_0000044962. FT SITE 19 19 May be involved in voltage sensor FT trapping upon activation of sodium FT channel. FT MOD_RES 37 37 Serine amide. FT DISULFID 2 18 FT DISULFID 9 23 FT DISULFID 17 33 FT DISULFID 25 31 FT MUTAGEN 3 3 V->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 5 5 D->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 7 7 Q->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 8 8 R->A: 51-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 8 8 R->D: More than 80-fold decrease in FT binding affinity and 5-fold decrease in FT toxicity. FT MUTAGEN 11 11 S->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 12 12 W->A: More than 160-fold decrease in FT binding affinity and nonsignificant FT differences in lethal dose. FT MUTAGEN 12 12 W->F: 13.5-fold decrease in binding FT affinity and more than 8-fold decrease in FT toxicity. FT MUTAGEN 13 13 S->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 16 16 Y->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 19 19 D->A: Nonsignificant differences in FT binding affinity and 2.9-fold decrease in FT toxicity. FT MUTAGEN 21 21 Y->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 22 22 Y->A: 54-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 24 24 S->A: 40-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 26 26 R->A: 16-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 28 28 M->A: 28-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 30 30 Y->A: 58-fold decrease in binding FT affinity and 5.1-fold decrease in FT toxicity. FT MUTAGEN 30 30 Y->F: 16-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 32 32 R->A: 24-fold decrease in binding FT affinity and 2.3-fold decrease in FT toxicity. FT MUTAGEN 34 34 R->A: 18-fold decrease in binding FT affinity and nonsignificant differences FT in lethal dose. FT MUTAGEN 35 35 N->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 36 36 N->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT MUTAGEN 37 37 S->A: Nonsignificant differences nor in FT binding affinity neither in lethal dose. FT STRAND 5 8 FT TURN 11 13 FT STRAND 22 24 FT STRAND 27 30 FT STRAND 32 34 SQ SEQUENCE 37 AA; 4124 MW; 861E12C2EB547716 CRC64; ACVGDGQRCA SWSGPYCCDG YYCSCRSMPY CRCRNNS //